Comparative Pharmacology
Head-to-head clinical analysis: AUKELSO versus OXICONAZOLE NITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUKELSO versus OXICONAZOLE NITRATE.
AUKELSO vs OXICONAZOLE NITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the mammalian target of rapamycin (mTOR) kinase, specifically the mTORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Oxiconazole nitrate is an azole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This leads to increased membrane permeability and cell death.
400 mg orally twice daily with food.
Apply a thin layer to affected skin once daily for 2 weeks for tinea pedis, tinea cruris, and tinea corporis.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Terminal elimination half-life is approximately 20-30 hours, allowing once-daily or twice-daily topical application.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Primarily biliary/fecal: >75% of dose excreted unchanged and as metabolites in feces via bile; renal excretion accounts for <10% (mostly inactive metabolites).
Category C
Category C
Topical Antifungal
Topical Antifungal